<div class="white-sheet">
	<div class="content-slide">

		<!-- Secondary scene 1 -->
		<div class="content secondary-scene">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-6">

			<div class="vertical-nav">
                <ul class="two">
                    <li class="active"></li>
                    <li></li>
                </ul>
            </div>

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>

			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia:<br /> eltrombopag treatment is generally well tolerated
			</div>


			<div class="content-container">

				<table class="red">
					<tr>
						<th>Patient identifier</td>
						<th>Adverse events leading to eltrombopag dose interruption or reduction</td>
					</tr>
					<tr class="odd">
						<td>35</td>
						<td>
							<ul>
								<li><span>Nausea and vomiting</span></li>
							</ul>
						</td>
					</tr>
					<tr>
						<td>44</td>
						<td>
							<ul>
								<li><span>Two interruptions with dose reductions due to elevated liver enzymes </span></li>
								<li><span>One interruption after hospitalisation</span>
									<ul>
										<li><span>Febrile neutropenia and abdominal pain</span></li>
									</ul>
								</li>
							</ul>
						</td>
					</tr>
					<tr class="odd">
						<td>17</td>
						<td>
							<ul>
								<li><span>Two interruptions due to serious adverse events (AEs)</span>
									<ul>
										<li><span>Two interruptions due to serious adverse events (AEs)</span>
											<ul>
												<li><span>Sepsis, <i>Clostridium difficile</i> colitis</span></li>
												<li><span>Neutropenia and hypotension</span></li>
											</ul>
										</li>
									</ul>
								</li>
							</ul>
						</td>
					</tr>
					<tr style="background: #C41230;height: 51px;color: #FFF;font-size: 20px;">
						<th>Patient identifier</th>
						<th>Adverse events leading to eltrombopag discontinuation</th>
					</tr>
					<tr class="odd">
						<td>5</td>
						<td>
							<ul>
								<li><span>Suspected cataract</span></li>
							</ul>
						</td>
					</tr>
					<tr>
						<td>6</td>
						<td>
							<ul>
								<li><span>Abdominal discomfort</span></li>
							</ul>
						</td>
					</tr>
					<tr class="odd">
						<td>21</td>
						<td>
							<ul>
								<li><span>Acute hepatitis B</span></li>
							</ul>
						</td>
					</tr>
					<tr>
						<td>24</td>
						<td>
							<ul>
								<li><span>Sepsis</span></li>
							</ul>
						</td>
					</tr>
				</table>

			</div>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ELT112523.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014 </span></li>
			</ul>

		</div>

		<div class="information-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: eltrombopag treatment generally well tolerated</header>
				
			<ul>
				<li><span>Four patients (9%) discontinued eltrombopag treatment because of an adverse event (AE)</span>
					<ul>
						<li><span>No event led to discontinuation in more than one patient</span></li>
						<li><span>These results reflect the known AE profile of eltrombopag and the events expected in a SAA patient population</span></li>
					</ul>
				</li>
			</ul>

		</div>

		</div>

		<!-- End of secondary scene 1 -->
		<!-- Secondary scene 2 -->
		<div class="content secondary-scene">

		<div class="title-bar blue"></div>

		<div class="wrapper slide-3-3-6a">

			<div class="vertical-nav">
                <ul class="two">
                    <li></li>
                    <li class="active"></li>
                </ul>
            </div>

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information2-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title blue two-line">
				Phase II study in refractory aplastic anaemia: <br />common adverse events
			</div>


			<div class="content-container" style="overflow-y: scroll;-webkit-overflow-scrolling: touch;">

				<table class="blue">
					<tr>
						<th>Adverse events occurring in ≥10% of patients</th>
						<th>Patients (N=43), n (%)</th>
					</tr>
					<tr class="odd">
						<td>Any event</td>
						<td>40 (93)</td>
					</tr>
					<tr>
						<td>Nausea</td>
						<td>14 (33)</td>
					</tr>
					<tr class="odd">
						<td>Fatigue</td>
						<td>12 (28)</td>
					</tr>
					<tr>
						<td>Cough</td>
						<td>10 (23)</td>
					</tr>
					<tr class="odd">
						<td>Diarrhoea</td>
						<td>9 (21)</td>
					</tr>
					<tr>
						<td>Headache</td>
						<td>9 (21)</td>
					</tr>
					<tr class="odd">
						<td>Pain in extremity</td>
						<td>8 (19)</td>
					</tr>
					<tr>
						<td>Dyspnoea</td>
						<td>6 (14)</td>
					</tr>
					<tr class="odd">
						<td>Pyrexia</td>
						<td>6 (14)</td>
					</tr>
					<tr>
						<td>Dizziness</td>
						<td>6 (14)</td>
					</tr>
					<tr class="odd">
						<td>Oropharyngeal paint</td>
						<td>6 (14)</td>
					</tr>
					<tr>
						<td>Febrile neutropenia</td>
						<td>6 (14)</td>
					</tr>
					<tr class="odd">
						<td>Abdominal pain</td>
						<td>5 (12)</td>
					</tr>
					<tr>
						<td>Ecchymosis</td>
						<td>5 (12)</td>
					</tr>
					<tr class="odd">
						<td>Muscle spasms</td>
						<td>5 (12)</td>
					</tr>
					<tr>
						<td>Elevated transaminases</td>
						<td>5 (12)</td>
					</tr>
					<tr class="odd">
						<td>Arthralgia</td>
						<td>5 (12)</td>
					</tr>
					<tr>
						<td>Rhinorrhoea</td>
						<td>5 (12)</td>
					</tr>
				</table>

			</div>

		</div>


		<div class="references2-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ELT112523.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014 </span></li>
			</ul>

		</div>


		<div class="information2-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: common adverse events </header>
				
			<ul>
				<li><span>Investigator deemed that 30 patients (70%) had at least one AE related to treatment</span></li>
				<li><span>Nausea, fatigue, cough, diarrhoea and headache were the most common events considered related to eltrombopag treatment, occurring in ≥20% of patients</span></li>
				<li><span>The AEs observed reflect the well-known safety profile of eltrombopag and events expected in this patient population</span></li>
				<li><span>Exposure to eltrombopag: </span>
					<ul>
						<li><span>Patient daily dose (mg)</span>
							<ul>
								<li><span>Mean (SD): 113.5 (19.69)</span></li>
								<li><span>Median (range): 110.2 (47–146)</span></li>
							</ul>
						</li>
						<li><span>Time on study treatment (months)</span>
							<ul>
								<li><span>Mean (SD): 7.5 (9.32)</span></li>
								<li><span>Median (range): 3.6 (2–37)</span></li>
							</ul>
						</li>
						<li><span>Treatment duration, n (%)</span>
							<ul>
								<li><span>&gt;3 months: 10 (23); ≥3 months: 33 (77); &lt;6 months: 11 (26); &lt;12 months: 7 (16)</span></li>
							</ul>
						</li>
						<li><span>Cumulative actual dose (mg)</span>
							<ul>
								<li><span>Mean (SD): 29165.1 (40869.65)</span></li>
								<li><span>Median (range): 10025.0 (4025–159650)</span></li>
							</ul>
						</li>
					</ul>
				</li>
			</ul>

		</div>

		</div>
		<!-- End of secondary scene 2 -->

	</div>
</div>